Cargando…

Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis

Background: Cognitive dysfunction occurs at the earliest stages of multiple sclerosis (MS), including the stage of clinically isolated syndrome (CIS). Methods: We evaluated the impact of interferon beta-1b (IFNβ-1b) 250 µg on cognitive performance during the CIS stage in the BENEFITstudy. Cognition...

Descripción completa

Detalles Bibliográficos
Autores principales:	Penner, Iris-Katharina, Stemper, Brigitte, Calabrese, Pasquale, Freedman, Mark S, Polman, Chris H, Edan, Gilles, Hartung, Hans-Peter, Miller, David H, Montalbán, Xavier, Barkhof, Frederik, Pleimes, Dirk, Lanius, Vivian, Pohl, Christoph, Kappos, Ludwig, Sandbrink, Rupert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2012
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573673/ https://www.ncbi.nlm.nih.gov/pubmed/22492127 http://dx.doi.org/10.1177/1352458512442438

Ejemplares similares

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT
por: Edan, G, et al.
Publicado: (2014)

Molecular mechanism underlying the impact of vitamin D on disease activity of MS
por: Munger, Kassandra L, et al.
Publicado: (2014)

Correction: Prognostic implications of a carefully performed neurological assessment in patients with a first event suggestive of multiple sclerosis
por: Nielsen, Jessica M, et al.
Publicado: (2011)

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial
por: Kappos, Ludwig, et al.
Publicado: (2016)

MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome
por: Nielsen, Jessica M, et al.
Publicado: (2009)

Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis
por: Freedman, MS, et al.
Publicado: (2012)

Predictors of disease activity in 857 patients with MS treated with interferon beta-1b
por: Hartung, Hans-Peter, et al.
Publicado: (2015)

Variability in detection and quantification of interferon β-1b–induced neutralizing antibodies
por: Hartung, Hans-Peter, et al.
Publicado: (2012)

Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes
por: De Stefano, Nicola, et al.
Publicado: (2014)

Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study
por: Freedman, Mark S., et al.
Publicado: (2014)

Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis
por: van den Elskamp, I. J., et al.
Publicado: (2010)

Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
por: Cohen, Jeffrey A, et al.
Publicado: (2016)

Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing‐remitting multiple sclerosis
por: Langdon, Dawn W., et al.
Publicado: (2021)

Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta‐1a
por: Battaglini, Marco, et al.
Publicado: (2022)

Case-Based fMRI Analysis after Cognitive Rehabilitation in MS: A Novel Approach
por: Hubacher, Martina, et al.
Publicado: (2015)

Introduction
por: Polman, Chris H., et al.
Publicado: (2007)

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
por: Barkhof, Frederik, et al.
Publicado: (2019)

Levels of brain‐derived neurotrophic factor in patients with multiple sclerosis
por: Naegelin, Yvonne, et al.
Publicado: (2020)

Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML
por: Fischer-Barnicol, Bettina, et al.
Publicado: (2020)

Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions
por: Elliott, Colm, et al.
Publicado: (2018)

Differential diagnosis of suspected multiple sclerosis: a consensus approach
por: Miller, DH, et al.
Publicado: (2008)

Clinical effects of natalizumab on multiple sclerosis appear early in treatment course
por: Kappos, Ludwig, et al.
Publicado: (2013)

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study
por: Cohen, Jeffrey A, et al.
Publicado: (2018)

Cognitive Dysfunction in Early Multiple Sclerosis: Altered Centrality Derived from Resting-State Functional Connectivity Using Magneto-Encephalography
por: Hardmeier, Martin, et al.
Publicado: (2012)

Type I interferon, anti-interferon antibodies, and COVID-19
por: Calabrese, Leonard H, et al.
Publicado: (2021)

Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration
por: Kearney, H, et al.
Publicado: (2014)

Coaching and talent development in esports: a theoretical framework and suggestions for future research
por: Bubna, Kabir, et al.
Publicado: (2023)

Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis
por: Elliott, Colm, et al.
Publicado: (2019)

Cerebellar Abnormalities Contribute to Disability Including Cognitive Impairment in Multiple Sclerosis
por: Weier, Katrin, et al.
Publicado: (2014)

The spatio-temporal relationship between white matter lesion volume changes and brain atrophy in clinically isolated syndrome and early multiple sclerosis
por: Mattiesing, Rozemarijn M., et al.
Publicado: (2022)

The spatio-temporal relationship between concurrent lesion and brain atrophy changes in early multiple sclerosis: A post-hoc analysis of the REFLEXION study
por: Gentile, Giordano, et al.
Publicado: (2023)

Activation of Vago by interferon regulatory factor (IRF) suggests an interferon system-like antiviral mechanism in shrimp
por: Li, Chaozheng, et al.
Publicado: (2015)

Harmonization of neuroimaging biomarkers for neurodegenerative diseases: A survey in the imaging community of perceived barriers and suggested actions
por: Jovicich, Jorge, et al.
Publicado: (2019)

N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry
por: Jasperse, Bas, et al.
Publicado: (2007)

Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis
por: Radue, Ernst-Wilhelm, et al.
Publicado: (2015)

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a
por: Havrdová, Eva, et al.
Publicado: (2018)

For patients with rheumatic disease and hepatitis C infection: the end of interferon
por: Calabrese, Leonard H, et al.
Publicado: (2015)

Defining the clinical course of multiple sclerosis: The 2013 revisions
por: Lublin, Fred D., et al.
Publicado: (2014)

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
por: Polman, Chris H, et al.
Publicado: (2011)

Cognitive and Clinical Dysfunction, Altered MEG Resting-State Networks and Thalamic Atrophy in Multiple Sclerosis
por: Tewarie, Prejaas, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_e9q1np702vk5hrapf51pa125pq